The role of new inflammatory indices in the prediction of endoscopic and histological activity in inflammatory bowel disease patients.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
18
9
2024
Statut:
aheadofprint
Résumé
Inflammatory indices are promising indicators that can be used to evaluate inflammation in inflammatory bowel diseases (IBDs). The present study aimed to investigate the test accuracy of several inflammatory indices to identify endoscopic, and histological activity in a cohort of IBD patients. All IBD patients who underwent colonoscopy and blood examination (within 4 weeks and without therapeutic change) were included. For these patients, 10 different inflammatory biomarkers were collected. Our primary outcome was the assessment of accuracy [evaluated with a receiver operating characteristics (ROC) analysis] of each inflammatory biomarker and indices. Furthermore, we tried to establish the optimal cutoff to identify patients with endoscopic and histologic activity among the inflammatory biomarkers and indices with higher performance. Regarding endoscopic activity, at the ROC analysis, the systemic inflammation response index (SIRI) showed the best accuracy [area under the curve (AUC), 0.627; confidence interval (CI), 0.552-0.698]. Whereas the ROC analysis showed a suboptimal AUC for the neutrophil-to-lymphocytes ratio (NLR) and platelets-to-lymphocytes ratio; (AUC, 0.620; CI, 0.545-0.691 and AUC, 0.607; CI, 0.532-0.679, respectively). Concerning histological activity, the C-reactive protein albumin ratio (CAR) presented a higher accuracy among the calculated inflammatory biomarkers (AUC, 0.682; CI, 0.569-0.781) while SIRI and NLR presented a subdued diagnostic performance. SIRI and CAR presented the best test accuracy in an IBD outpatient setting to identify endoscopic and histological activity. However, the test accuracy of all the evaluated Inflammatory indices appeared suboptimal. Fecal calprotectin has still the highest accuracy in predicting endoscopic and histological activity in patients with IBD.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Inflammatory indices are promising indicators that can be used to evaluate inflammation in inflammatory bowel diseases (IBDs). The present study aimed to investigate the test accuracy of several inflammatory indices to identify endoscopic, and histological activity in a cohort of IBD patients.
STUDY
METHODS
All IBD patients who underwent colonoscopy and blood examination (within 4 weeks and without therapeutic change) were included. For these patients, 10 different inflammatory biomarkers were collected. Our primary outcome was the assessment of accuracy [evaluated with a receiver operating characteristics (ROC) analysis] of each inflammatory biomarker and indices. Furthermore, we tried to establish the optimal cutoff to identify patients with endoscopic and histologic activity among the inflammatory biomarkers and indices with higher performance.
RESULTS
RESULTS
Regarding endoscopic activity, at the ROC analysis, the systemic inflammation response index (SIRI) showed the best accuracy [area under the curve (AUC), 0.627; confidence interval (CI), 0.552-0.698]. Whereas the ROC analysis showed a suboptimal AUC for the neutrophil-to-lymphocytes ratio (NLR) and platelets-to-lymphocytes ratio; (AUC, 0.620; CI, 0.545-0.691 and AUC, 0.607; CI, 0.532-0.679, respectively). Concerning histological activity, the C-reactive protein albumin ratio (CAR) presented a higher accuracy among the calculated inflammatory biomarkers (AUC, 0.682; CI, 0.569-0.781) while SIRI and NLR presented a subdued diagnostic performance.
CONCLUSION
CONCLUSIONS
SIRI and CAR presented the best test accuracy in an IBD outpatient setting to identify endoscopic and histological activity. However, the test accuracy of all the evaluated Inflammatory indices appeared suboptimal. Fecal calprotectin has still the highest accuracy in predicting endoscopic and histological activity in patients with IBD.
Identifiants
pubmed: 39292974
doi: 10.1097/MEG.0000000000002842
pii: 00042737-990000000-00406
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015; 12:205–217.
Saeid Seyedian S, Nokhostin F, Dargahi Malamir M. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life 2019; 12:113–122.
Verstockt B, Bressler B, Martinez-Lozano H, McGovern D, Silverberg MS. Time to revisit disease classification in inflammatory bowel disease: is the current classification of inflammatory bowel disease good enough for optimal clinical management? Gastroenterology 2022; 162:1370–1382.
Kumar M, Garand M, Al Khodor S. Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine. J Transl Med 2019; 17:419.
Vasant DH, Ford AC. Functional gastrointestinal disorders in inflammatory bowel disease: Time for a paradigm shift? World J Gastroenterol 2020; 26:3712–3719.
Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol 2019; 20:970–979.
Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021; 6:589–595.
Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al.; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019; 13:144–164.
Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 2012; 159:313–325.
Rogler G, Biedermann L. Clinical utility of biomarkers in IBD. Curr Gastroenterol Rep 2015; 17:26.
Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease. Inflamm Bowel Dis 2017; 23:894–902.
Rokkas T, Portincasa P, Koutroubakis IE. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis 2018; 27:299–306.
Lasson A, Öhman L, Stotzer PO, Isaksson S, Überbacher O, Ung K-A, Strid H. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: a prospective, randomized, controlled study. United European Gastroenterol J 2015; 3:72–79.
Diederen K, Hoekman DR, Leek A, Wolters VM, Hummel TZ, de Meij TG, et al. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission. Aliment Pharmacol Ther 2017; 45:951–960.
Du L, Foshaug R, Huang VW, Kroeker KI, Dieleman LA, Halloran BP, et al. Within-stool and within-day sample variability of fecal calprotectin in patients with inflammatory bowel disease. J Clin Gastroenterol 2018; 52:235–240.
Chen JM, Liu T, Gao S, Tong X-D, Deng F-H, Nie B. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: a prospective study in China. World J Gastroenterol 2017; 23:8235–8247.
Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 2015; 110:802–19; quiz 820.
Wright EK, Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Keenan JI, et al. Comparison of fecal inflammatory markers in Crohnʼs Disease. Inflamm Bowel Dis 2016; 22:1086–1094.
Höög CM, Bark LA, Broström O, Sjöqvist U. Capsule endoscopic findings correlate with fecal calprotectin and C-reactive protein in patients with suspected small-bowel Crohn’s disease. Scand J Gastroenterol 2014; 49:1084–1090.
Zhou Q, Su S, You W, Wang T, Ren T, Zhu L. Systemic inflammation response index as a prognostic marker in cancer patients: a systematic review and meta-analysis of 38 cohorts. Dose-Response 2021; 19:155932582110647.
Simonaggio A, Elaidi R, Fournier L, Fabre E, Ferrari V, Borchiellini D, et al. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother 2020; 69:2513–2522.
Wang J, Li J, Wei S, Xu J, Jiang X, Yang L. The ratio of platelets to lymphocytes predicts the prognosis of metastatic colorectal cancer: a review and meta-analysis. Gastroenterol Res Pract 2021; 2021:1–8.
Holub K, Biete A. New pre-treatment eosinophil-related ratios as prognostic biomarkers for survival outcomes in endometrial cancer. BMC Cancer 2018; 18:1.
Frey A, Martin D, D’Cruz L, Fokas E, Rödel C, Fleischmann M. C-Reactive protein to albumin ratio as prognostic marker in locally advanced non-small cell lung cancer treated with chemoradiotherapy. Biomedicines 2022; 10:598.
Lin KB, Fan FH, Cai MQ, Yu Y, Fu C-L, Ding L-Y, et al. Systemic immune inflammation index and system inflammation response index are potential biomarkers of atrial fibrillation among the patients presenting with ischemic stroke. Eur J Med Res 2022; 27:106.
Ghobadi H, Mohammadshahi J, Javaheri N, Fouladi N, Mirzazadeh Y, Aslani MR. Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts in-hospital mortality in non-elderly and elderly COVID-19 patients. Front Med (Lausanne) 2022; 9:916453.
Xu Y, He H, Zang Y, Yu Z, Hu H, Cui J, et al. Systemic inflammation response index (SIRI) as a novel biomarker in patients with rheumatoid arthritis: a multi-center retrospective study. Clin Rheumatol 2022; 41:1989–2000.
Mondal S, Guha S, Saha A, Ghoshal L, Bandyopadhyay D. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in chronic plaque psoriasis. Indian J Dermatol 2022; 67:477.
Sarhan SA, EL-Meligui YM. Significance of platelets to lymphocytes and platelets to haemoglobin ratios in patients with systemic sclerosis. Reumatol Clin 2023; 19:12–17.
Header DA, Aboelwafa RA, Elkeleny MR, Bedewy ES, Ellakany AI. C-reactive protein/albumin ratio (CAR) as a marker for detecting acute severe ulcerative colitis in Egyptian patients. Rev Gastroenterol Mex (Engl Ed) 2022; 87:447–454.
Pakoz ZB, Ustaoglu M, Vatansever S, Yuksel ES, Topal F. Serum Immune-Inflammation Index Assessment in the Patients with Ulcerative Colitis. Gastroenterol Res Pract 2022; 2022:1–5.
Yu T, Yu Q, Ou X, Cao D. Systemic inflammation response index (SIRI) as a predictor for predicting inflammatory bowel disease (IBD) severity. Biomed Res 2018; 29:938–944.
Acarturk G, Acay A, Demir K, Ulu MS, Ahsen A, Yuksel S. Neutrophil-to-lymphocyte ratio in inflammatory bowel disease – AS a new predictor of disease severity. Bratisl Lek Listy 2015; 116:213–217.
Akpinar MY, Ozin YO, Kaplan M, Ates I, Kalkan IH, Kilic ZMY, et al. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio predict mucosal disease severity in ulcerative colitis. J Med Biochem 2018; 37:155–162.
Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007; 4:e296.
Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, et al.; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR guideline for diagnostic assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019; 13:273–284.
Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. J Crohns Colitis 2014; 8:1582–1597.
Lin H, Bai Z, Wu Q, Chu G, Zhang Y, Guo X, Qi X. Inflammatory indexes for assessing the severity and disease progression of ulcerative colitis: a single-center retrospective study. Front Public Health 2022; 10:851295.
Feng W, Liu Y, Zhu L, Xu L, Shen H. Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential markers for ulcerative colitis: a retrospective study. BMC Gastroenterol 2022; 22:1.
Bertani L, Rossari F, Barberio B, Demarzo MG, Tapete G, Albano E, et al. Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-TNF: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio. Inflamm Bowel Dis 2020; 26:1579–1587.
Chen R, Li C, Chao K, Tie Y, Zheng J, Guo H, et al. Neutrophil-to-lymphocyte ratio for predicting postoperative recurrence in Crohn’s disease patients with isolated anastomotic lesions. Therap Adv Gastroenterol 2023; 16:175628482311651.
Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015; 110:444–454.
Valvano M, Magistroni M, Mancusi A, D'Ascenzo D, Longo S, Stefanelli G, et al. The Usefulness of serum vitamin D levels in the assessment of IBD activity and response to biologics. Nutrients 2021; 13:323.
Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al.; International Organization for the Study of IBD. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160:1570–1583.
Viscido A, Valvano M, Stefanelli G, Capannolo A, Castellini C, Onori E, et al. Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. BMC Gastroenterol 2022; 22:92.
Park S, Abdi T, Gentry M, Laine L. Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2016; 111:1692–1701.